Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1
Phase 1
55
about 4.7 years
18+
4 sites in IL, KY, MD +1
What this study is about
This trial is testing the safety and how well a new drug, ²¹²Pb-DOTAM-GRPR1, works in adults with cancer that has returned or spread. The goal is to find out if this treatment can be safely given to people with recurrent or metastatic GRPR-expressing tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ²¹²Pb-DOTAM-GRPR1
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: To assess PK of ²¹²Pb-DOTAM-GRPR1, To assess the safety and tolerability of 203Pb-DOTAM-GRPR1., To assess the safety and tolerability of 212Pb-DOTAM-GRPR1.
Oncology